We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
CBRE Group
CBRE
$40.8B
| $17M | 0.23% |
320,306
+687
| +0.2% | +$36.1K |
|
102
Grupo Cibest SA
CIB
$20.4B
| $16.9M | 0.22% |
342,589
+336,275
| +5,326% | +$17M |
|
103
Lowe's Companies
LOW
$116B
| $16.9M | 0.22% |
153,499
+8,535
| +6% | +$901K |
|
104
NextEra Energy
NEE
$187B
| $16.8M | 0.22% |
287,964
-161,116
| -36% | -$8.72M |
|
|
ARNA
105
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $16.7M | 0.22% |
365,800
+83,000
| +29% | +$4.67M |
|
106
Booking.com
BKNG
$138B
| $16.4M | 0.22% |
209,125
-21,350
| -9% | -$1.65M |
|
107
Trimble
TRMB
$12.3B
| $15.9M | 0.21% |
408,989
+56,235
| +16% | +$2.26M |
|
108
MetLife
MET
$61B
| $15.9M | 0.21% |
336,447
-10,803
| -3% | -$515K |
|
|
RETA
109
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $15.8M | 0.21% |
196,200
-53,000
| -21% | -$4.5M |
|
110
Kinder Morgan
KMI
$73.1B
| $15.7M | 0.21% |
763,087
+151,180
| +25% | +$3.1M |
|
|
SPLK
111
DELISTED
Splunk Inc
SPLK
| $15.7M | 0.21% |
133,217
+54,035
| +68% | +$6.75M |
|
112
Mondelez International
MDLZ
$77.7B
| $15.6M | 0.21% |
282,507
-26,984
| -9% | -$1.48M |
|
113
TAL Education Group
TAL
$5.71B
| $15.6M | 0.21% |
455,745
-447,200
| -50% | -$15.6M |
|
|
BLUE
114
DELISTED
bluebird bio
BLUE
| $15.5M | 0.21% |
13,055
| – | – |
|
115
Global Payments
GPN
$22.1B
| – | – |
-46,585
| Closed | -$7.6M |
|
116
3M
MMM
$89B
| $15.3M | 0.2% |
111,638
-51,773
| -32% | -$7.24M |
|
117
Becton Dickinson
BDX
$43.1B
| $15.3M | 0.2% |
62,011
+1,009
| +2% | +$249K |
|
118
Alnylam Pharmaceuticals
ALNY
$36.3B
| $15.3M | 0.2% |
190,073
-191,651
| -50% | -$15.2M |
|
119
Air Products & Chemicals
APD
$66.3B
| $15.1M | 0.2% |
68,283
+2,378
| +4% | +$535K |
|
120
Fortinet
FTNT
$112B
| $14.8M | 0.2% |
965,540
+633,010
| +190% | +$10.3M |
|
121
Franklin Resources
BEN
$16.9B
| $14.7M | 0.2% |
509,836
+164,569
| +48% | +$5.03M |
|
122
Netflix
NFLX
$292B
| $14.7M | 0.19% |
548,660
+54,920
| +11% | +$1.72M |
|
123
Sarepta Therapeutics
SRPT
$1.66B
| $14.5M | 0.19% |
192,600
| – | – |
|
124
Monster Beverage
MNST
$91.4B
| $14.4M | 0.19% |
494,792
-81,196
| -14% | -$2.46M |
|
125
Advanced Micro Devices
AMD
$851B
| $14.3M | 0.19% |
492,930
+105,713
| +27% | +$3.32M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.